Biopesticide preparation prepared from bacillus subtilis metabolite and application

By combining crude protein and crude lipopeptide in Bacillus subtilis fermentation broth, as well as specific antimicrobial peptides, combined with additives, a biopestic preparation for preventing and treating kiwi fruit soft rot was prepared, solving the prevention and treatment effect in the prior art The problem of instability and preparation technology need to be optimized has achieved the goal of effective control and environmental protection of kiwi fruit soft rot.

CN118947733APending Publication Date: 2024-11-15GUIZHOU UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411080092.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, Bacillus subtilis metabolites have problems such as unstable prevention and treatment effects, unclear stability and mechanism of action, and the need to optimize preparation technology in the prevention and treatment of soft rot of kiwi fruit, resulting in challenges in their practical applications.

Method used

Prepare biopestic preparations using metabolites extracted from Bacillus subtilis fermentation process, including crude protein and crude lipopeptide in sterile fermentation broth, as well as antimicrobial peptides synthesized through specific target genes, combining nonionic surfactants, stabilizers, Wetting agents and sustained release agents form easy-to-applicable biopesticide preparations.

Benefits of technology

It improves the inhibitory effect on kiwi soft rot pathogens, reduces the risk of environmental pollution and the negative impact on non-target organisms, enhances the stability and application performance of the preparations, and provides an environmentally friendly and effective disease control method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118947733A_ABST
    Figure CN118947733A_ABST
Patent Text Reader

Abstract

The invention discloses a biopesticide preparation prepared from bacillus subtilis metabolite and application, the biopesticide preparation comprises metabolite extracted in the fermentation process of bacillus subtilis, and the metabolite comprises crude protein and crude lipopeptide extracted from sterile fermentation liquor or high-temperature sterile fermentation liquor of bacillus subtilis. And one or a combination thereof of antimicrobial peptides synthesized via a specific target gene. The biological pesticide preparation can be applied to prevention and treatment of kiwi fruit diseases. According to the biological pesticide preparation disclosed by the invention, by changing the morphological structure of pathogenic bacteria hyphae, the preparation can effectively inhibit main pathogenic bacteria of kiwi fruit soft rot such as botryosphaeria dothidea, alternaria alternata and phomopsis, so that the occurrence and spreading of diseases are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of bio-agriculture and related industries, and particularly relates to a microbial-derived biopesticide, in particular a preparation method of a Bacillus subtilis metabolite and its use in preventing and controlling kiwifruit diseases. Background Art

[0002] Kiwifruit (Actinidia deliciosa) is a highly commercially valuable fruit, but it is susceptible to soft rot during growth and storage, resulting in significant yield and quality losses. Soft rot is primarily caused by pathogens such as Botryosphaeria dothidea, Alternaria alternata, and Phomopsis sp. While traditional chemical pesticides have limited disease control, long-term application can lead to environmental pollution, increased pathogen resistance, and negative impacts on non-target organisms.

[0003] In recent years, with increasing awareness of food safety and environmental protection, the development of novel, environmentally friendly biopesticides has become a key focus for sustainable agricultural development. Microbial-derived biopesticides have garnered widespread attention due to their unique biological activity and low environmental risk. Bacillus subtilis, a widely studied antagonistic bacterium, has been shown to produce a variety of metabolites with antibacterial, antiviral, and antifungal activities, including lipopeptides and peptide antibiotics.

[0004] Despite the potential of Bacillus subtilis metabolites for biocontrol, their practical application still faces several challenges. First, the types and quantities of metabolites produced by different Bacillus subtilis strains vary, resulting in unstable control effects. Second, the stability and mechanism of action of the metabolites are not fully understood, limiting their application under different environmental conditions. Furthermore, the formulation technology of Bacillus subtilis metabolites needs to be further optimized to improve their operability and cost-effectiveness in actual production. Summary of the Invention

[0005] In view of the deficiencies in the prior art, the present invention provides a biological pesticide preparation prepared from Bacillus subtilis metabolites and its use in preventing and controlling kiwifruit soft rot.

[0006] Based on the first main aspect of the present invention, a biopesticide preparation prepared using Bacillus subtilis metabolites is provided. The biopesticide preparation comprises metabolites extracted from the fermentation process of Bacillus subtilis, wherein the metabolites include crude protein and crude lipopeptides extracted from the sterile fermentation broth or high-temperature sterile fermentation broth of Bacillus subtilis, and one or a combination of antimicrobial peptides synthesized via specific target genes.

[0007] These metabolites can directly act on pathogens, interfering with their growth and reproduction, thereby effectively controlling the occurrence and spread of kiwifruit soft rot. Furthermore, the biogenic nature of the formulation gives it a low risk of environmental contamination and safety against non-target organisms.

[0008] The high-temperature sterile fermentation broth is obtained by sterilizing the sterile fermentation broth of Bacillus subtilis obtained by conventional methods in a high-pressure steam sterilizer at 120°C for 20 minutes. The main purpose is to facilitate the separation of the high-temperature resistant crude lipopeptides and crude proteins therein.

[0009] As a further preferred embodiment, the specific target gene is an antimicrobial peptide synthetic gene determined by PCR detection using 14 pairs of primers; the synthetic antimicrobial peptide includes one or a combination of the antimicrobial lipopeptide Surfactin, BasiliskamideA / ThailanstatinB, Bacillibactin (siderophore structure), Bacillaene (polyketide), Fengycin, Bacilysin, SubtilosinA and Luminmide.

[0010] These antimicrobial peptides are encoded by specific target genes in Bacillus subtilis. Fourteen primer pairs, identified through PCR testing, ensure that the selected strains contain the genes that synthesize these antimicrobial peptides, thereby ensuring the formulation's high efficacy and stability. The identification of antimicrobial peptides, including surfactin, basiliskamide A / Thailanstatin B, bacillibactin, bacillaene, fengycin, bacilysin, subtilosin A, and luminmide, enhances the formulation's inhibitory spectrum against pathogens and improves the applicability and effectiveness of the biopesticide.

[0011] The above antimicrobial peptides are disclosed in (“Research Progress on Biosynthesis of Antimicrobial Peptides from Bacillus subtilis[J]”. Zhao Pengchao, Wang Jianhua, Quan Chunshan, et al., Chinese Journal of Biotechnology, 2010, 30(10): 108-113. DOI: 10.13523 / j.cb.20101018.).

[0012] As a further preferred embodiment, the 14 pairs of primers have 16S rDNA sequences as shown in SEQ ID NO:1-SEQ ID NO:30. These sequence-specific primers can accurately screen and confirm Bacillus subtilis strains harboring the target antimicrobial peptide synthesis gene. This precise genetic screening provides molecular biological assurance for the quality and efficacy of the formulation.

[0013] As a further preferred embodiment, the biopesticide formulation contains one or more adjuvants, and the adjuvants are selected from at least one or a combination of the following: nonionic surfactants, stabilizers, wetting agents, and sustained-release agents.

[0014] Nonionic surfactants include polysorbate series, such as Polysorbate 80; fatty acid glycerides, such as Glyceryl Monostearate; polyethylene glycol (PEG) derivatives; and sorbitan series, such as Sorbitan Sesquioleate 60. Stabilizers include sodium carboxymethyl cellulose (CMC); xanthan gum; gelatin; and methylcellulose. Wetting agents include polyethylene glycol (PEG); glycerol; propylene glycol; and ethanol. Sustained-release agents include natural polymer materials, such as modified starch and chitosan; synthetic polymer materials, such as polylactic acid (PLA) and polyvinyl alcohol (PVA); liposomes; and inorganic materials, such as diatomaceous earth.

[0015] Adjuvants are key factors in formulation performance. The addition of nonionic surfactants, stabilizers, wetting agents, and sustained-release agents not only enhances the formulation's physical and chemical stability but also improves its performance in practical applications. Wetting agents and nonionic surfactants enhance the formulation's wettability and adhesion to plant surfaces, thereby increasing the bioavailability of the active ingredient. The use of stabilizers and sustained-release agents ensures formulation stability during storage and use, as well as slow release on plant surfaces or within the body, prolonging its efficacy and enhancing control effectiveness.

[0016] According to the second main aspect of the present invention, a method for preparing the above biopesticide formulation is provided, comprising the following steps:

[0017] Cultivate Bacillus subtilis in a suitable culture medium for up to 96 hours to obtain a bacterial solution rich in metabolites;

[0018] Sterile fermentation broth was obtained by centrifugation and filtration techniques;

[0019] The sterile fermentation liquid was diluted to determine the dilution multiple with the best inhibitory effect on kiwifruit soft rot pathogens;

[0020] Through crude protein extraction and crude lipopeptide separation technology, metabolites with significant antibacterial activity are further enriched; the metabolites obtained in the above steps are formulated to form biopesticide formulations that are easy to apply.

[0021] Among them, crude protein extraction and crude lipopeptide separation involve heat treatment of sterile fermentation broth under high temperature conditions to separate heat-stable components, including crude lipopeptides and crude protein, thereby increasing the concentration of target components and reducing heat-sensitive impurities.

[0022] The crude protein can be induced to precipitate by changing the pH or adding salts (such as ammonium sulfate or sodium chloride). The precipitated crude protein can be separated by centrifugation.

[0023] Crude lipopeptides can be isolated by exploiting the differences in solubility of lipopeptides in different solvents to extract the target components. For example, organic solvents or acidic / alkaline solutions can be used for extraction. The extracted lipopeptides can be precipitated by adding inorganic salts or changing the solvent polarity. The precipitated lipopeptides are then washed to remove soluble impurities.

[0024] In the above steps, the richness and diversity of metabolites are ensured by culturing Bacillus subtilis in a suitable culture medium for up to 96 hours. The sterile fermentation broth obtained through centrifugation and filtration techniques ensures the purity and safety of the preparation. The method improves the biological activity and application effect of the preparation by determining the dilution factor for optimal antibacterial effect and enriching metabolites with significant antibacterial activity through dilution and crude extraction techniques. The final step of the formulation process makes the biopesticide preparation easy to apply and store, facilitating commercial production and application.

[0025] In some embodiments, the formulation process further comprises the following steps:

[0026] mixing the crude protein and crude lipopeptide obtained by extraction and separation with an appropriate amount of stabilizer to form a stable metabolite solution;

[0027] Adjust the pH of the metabolite solution to 6.5 to 7.5 to optimize the activity of the antimicrobial peptides;

[0028] adding a wetting agent and a nonionic surfactant to the metabolite solution to improve the wettability and adhesion of the formulation on the plant surface;

[0029] Sustained-release agents are added to control the release rate of metabolites and extend the shelf life of the preparation;

[0030] The metabolite solution is converted into a powder or granular preparation by spray drying or freeze drying technology for easy storage and administration.

[0031] In the above steps, crude protein and crude lipopeptide are mixed with a stabilizer to form a stable metabolite solution, which helps maintain the activity of the antimicrobial peptides and prevent their degradation. Adjusting the pH to 6.5 to 7.5 optimizes the activity of the antimicrobial peptides and enhances the antibacterial effect of the formulation. The addition of a wetting agent and a nonionic surfactant enhances the wettability and adhesion of the formulation on the plant surface, ensuring better coverage and penetration. The use of a sustained-release agent to control the release rate extends the shelf life of the formulation, reduces application frequency, and improves user convenience. Transformation through spray drying or freeze-drying technology provides a variety of formulation forms to suit different application requirements.

[0032] In some embodiments, the amount of the nonionic surfactant is 0.1% to 1.0% of the total weight of the formulation; the amount of the stabilizer is 0.05% to 0.5% of the total weight of the formulation; the amount of the wetting agent is 0.2% to 1.5% of the total weight of the formulation; and the amount of the sustained-release agent is 1.0% to 3.0% of the total weight of the formulation.

[0033] The above scheme clarifies the dosage range of adjuvants in the formulation, which has a significant impact on the stability, release characteristics and application effect of the formulation. The appropriate addition of non-ionic surfactants enhances the emulsification and dispersion ability of the formulation, helping to improve the bioavailability of the active ingredients. The appropriate use of stabilizers ensures the stability of the formulation during storage and transportation, preventing the decomposition and inactivation of the ingredients. The reasonable use of wetting agents improves the wettability of the formulation on the plant surface and enhances the uniformity of coverage. The addition of sustained-release agents achieves the slow release of metabolites, prolongs the efficacy, reduces the potential impact on the environment, and increases the possibility of pathogens developing resistance to the active ingredients in the formulation. The precise dosage of these adjuvants provides a guarantee for the high efficiency and environmental friendliness of the formulation.

[0034] The third main aspect of the present invention provides the use of the aforementioned biopesticide formulation for the prevention and control of kiwifruit diseases. Biopesticide formulations prepared using Bacillus subtilis metabolites provide kiwifruit growers with an environmentally friendly and effective disease control method. Compared to traditional chemical pesticides, biopesticide formulations have lower chemical residues and are more environmentally friendly, contributing to the sustainable development of agriculture.

[0035] The application involves using Bacillus subtilis metabolites to alter the morphological structure of pathogenic hyphae, thereby inhibiting their growth. This mechanism of action not only effectively controls the spread of pathogens but also reduces the risk of pathogens developing resistance to pesticides. Furthermore, this microbial metabolite-based disease control method provides new insights into the development of novel biopesticides, helping to enrich existing disease control methods.

[0036] The pathogens mentioned include Botrytis cinerea, Alternaria alternata, and Phomopsis spp. These pathogens are the primary causative agents of kiwifruit soft rot. Clearly identifying these pathogens helps users understand the formulation's scope of application and specificity, enabling more accurate application in disease management practices. Furthermore, this provides clear targets for formulation development and optimization, helping to further enhance its effectiveness and application value.

[0037] Advantages and beneficial effects of the present invention:

[0038] Compared to existing technologies, the present invention provides a biopesticide formulation based on Bacillus subtilis metabolites. Its innovation lies in the comprehensive utilization of multiple active ingredients produced during the fermentation process of Bacillus subtilis, including sterile fermentation broth, high-temperature sterile fermentation broth, crude protein solution, crude lipopeptides, and specific antimicrobial peptides. The synergistic effect of these ingredients enhances the formulation's inhibitory effect against kiwifruit soft rot pathogens. By accurately screening Bacillus subtilis strains containing key antimicrobial peptide synthesis genes through PCR testing, the present invention ensures the formulation's high efficiency and stability. Furthermore, by optimizing the type and dosage of adjuvants, the formulation's application performance and environmental adaptability are further improved.

[0039] The biopesticide formulation of the present invention features innovative preparation methods, including multiple steps, including strain screening, metabolite extraction, determination of the dilution factor, crude protein and crude lipopeptide enrichment, and formulation. These steps not only ensure the quality and concentration of the active ingredients in the formulation, but also, through pH adjustment, the addition of wetting agents and nonionic surfactants, the use of sustained-release agents, and drying techniques, enhance the formulation's stability, wettability, adhesion, and sustained-release properties. These characteristics make the formulation more convenient and effective in practical applications, while also reducing potential environmental impacts.

[0040] The biopesticide formulation of the present invention has significant application value in the prevention and control of agricultural diseases. By altering the morphological structure of pathogenic fungi's hyphae, the formulation can effectively inhibit major pathogens of kiwifruit soft rot, such as Botrytis cinerea, Alternaria alternata, and Phomopsis spp., thereby reducing the occurrence and spread of the disease. Compared with traditional chemical pesticides, the biopesticide formulation of the present invention has lower chemical residues, less environmental risk, and potential resistance risk. Furthermore, the formulation of the present invention provides new ideas and methods for the biological control of agricultural diseases, helping to promote the development of agriculture in a greener and more sustainable direction. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, without paying any creative work, other drawings obtained based on these drawings still fall within the scope of the present invention.

[0042] Figure 1 shows the growth curve of Bacillus subtilis in one embodiment of the present invention;

[0043] Figure 2 The figure shows the growth of kiwifruit soft rot pathogens after treatment with sterile fermentation liquid in one embodiment of the present invention;

[0044] Figure 3 The figure shows the growth of mycelium of kiwifruit soft rot pathogen after being treated with sterile fermentation liquid in one embodiment of the present invention;

[0045] Figure 4 The figure shows the growth of kiwifruit soft rot pathogens after treatment with high-temperature sterile fermentation liquid in one embodiment of the present invention;

[0046] Figure 5 The figure shows the growth of mycelium of kiwifruit soft rot pathogen after being treated with high-temperature sterile fermentation liquid in one embodiment of the present invention;

[0047] Figure 6 The figure shows the growth of kiwifruit soft rot pathogens after crude protein treatment in one embodiment of the present invention;

[0048] Figure 7 The figure shows the growth of mycelium of kiwifruit soft rot pathogen after crude protein treatment in one embodiment of the present invention;

[0049] Figure 8 The figure shows the growth of kiwifruit soft rot pathogens after crude lipopeptide treatment in one embodiment of the present invention;

[0050] Figure 9The figure shows the growth of mycelium of kiwifruit soft rot pathogen after treatment with crude lipopeptide in one embodiment of the present invention;

[0051] Figure 10 Shown is an electrophoresis diagram of antibacterial related gene detection in one embodiment of the present invention. DETAILED DESCRIPTION

[0052] The preferred embodiments of the present invention will be described in detail below so that the purpose, features and advantages of the present invention can be more clearly understood. It should be understood that the following embodiments are not intended to limit the scope of the present invention, but are only intended to illustrate the essential spirit of the technical solution of the present invention.

[0053] In the following description, for the purpose of illustrating the various disclosed embodiments, certain specific details are set forth in order to provide a thorough understanding of the various disclosed embodiments. However, those skilled in the relevant art will recognize that the embodiments may be practiced without one or more of these specific details. In other cases, well-known devices, structures, and techniques associated with this application may not be shown or described in detail to avoid unnecessarily obscuring the description of the embodiments.

[0054] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any manner in one or more embodiments.

[0055] Example 1:

[0056] 1. Growth curve of Bacillus subtilis

[0057] Depend on Figure 1 It can be seen that during the 0-6h period, the OD600 value hardly changed, indicating that the antagonistic strain grew slowly at this time; during the 6-24h period, the OD600 value increased, but the growth rate of the antagonistic strain was still slow; during the 24-48h period, the antagonistic strain grew rapidly and was in the logarithmic growth phase, and the value increased significantly; during the 48-96h period, the antagonistic strain was still growing, but the growth rate slowed down and gradually entered a stable period; after 96h, the value began to decrease, indicating that the antagonistic strain began to enter a decline period. Therefore, it can be determined that the time for the optimal concentration of the culture solution is about 96h, which paves the way for better completion of the preparation of sterile fermentation broth, high-temperature sterile fermentation broth, extraction of crude protein and crude lipopeptide experiments.

[0058] 2. Antibacterial effect of sterile fermentation liquid on kiwifruit soft rot pathogens

[0059] Depend on Figure 2 It can be seen that the antibacterial activity of sterile fermentation broths with different dilution ratios against kiwifruit soft rot pathogens varies, and the 10-fold dilution has the most significant antibacterial effect. In Table 1, the 10-fold dilution has the highest inhibition rate against the pathogen Botrytis cinerea, which is 71.33±7.51%, and the inhibition rate against Alternaria alternata is 64.00±2.08%, slightly lower than Botrytis cinerea. The antibacterial activity against Phomopsis spp. is the lowest, with an inhibition rate of 55.33±1.45%. Figure 3 It can be seen that compared with normally growing mycelium, the mycelium treated with sterile fermentation liquid showed local swelling, and the top of the mycelium was deformed into a spherical shape. It can be inferred that the sterile fermentation liquid inhibits the growth of pathogens by changing the mycelium structure.

[0060] Table 1 Antibacterial activity of sterile fermentation broth against kiwifruit soft rot pathogens

[0061]

[0062]

[0063] Note: The data in the table are mean ± standard error, and lowercase letters indicate significant differences at the 0.05 level.

[0064] 3. Antibacterial effect of high-temperature sterile fermentation liquid on kiwifruit soft rot pathogens

[0065] From Table 2, Figure 4 It can be seen that the antibacterial activity of high-temperature sterile fermentation broth at different dilution ratios on kiwifruit soft rot pathogens is different. The higher the concentration, the better the antibacterial effect. Among them, the antibacterial activity against Phomopsis spp. is the best, with an inhibition rate of 62.33±0.88%. The inhibition rates against Alternaria alternata and Botrytis cinerea are 47.67±0.88% and 46.00±1.73% respectively, and the antibacterial effect is not significant. Figure 5 It can be seen that the hyphae of Phomopsis and Botrytis cinerea treated with high temperature sterile fermentation liquid showed slight deformity and branching, while the hyphae of Alternaria alternata remained unchanged. Figure 3 In contrast, the effect of mycelium mutation is not obvious. From this, it can be speculated that the substances in the metabolites of Bacillus subtilis that can cause mycelium mutation of pathogens are not resistant to high temperatures.

[0066] Table 2 Antibacterial activity of high temperature sterile fermentation broth against kiwifruit soft rot pathogens

[0067]

[0068] Note: The data in the table are mean ± standard error, and lowercase letters indicate significant differences at the 0.05 level.

[0069] 4. Antibacterial activity of crude protein solution against kiwifruit soft rot pathogens

[0070] From Table 3, Figure 6 It can be seen that crude protein has a strong inhibitory effect on the growth of kiwifruit soft rot pathogens. The 10-fold dilution of crude protein has a good antibacterial effect on Alternaria alternata and Botrytis cinerea, with inhibition rates of 88.00±0.58% and 87±2.03% respectively, with no significant difference. However, the inhibition rate on the mycelial growth of Phomopsis rapae is 57.67±0.58%, with a weaker inhibitory effect, and there is a significant difference between the inhibition rates of the other two pathogens. Figure 7 In the experiment, the pathogens treated with crude protein solution showed abnormalities. The hyphae of Alternaria and Phomopsis showed swelling, and the hyphae of Botrytis cinerea showed small branches. Compared with the treatment, the hyphae mutation effect was obvious.

[0071] Table 3 Antibacterial activity of 10-fold diluted crude protein solution against kiwifruit soft rot pathogens

[0072]

[0073]

[0074] Note: The data in the table are mean ± standard error, and lowercase letters indicate significant differences at the 0.05 level.

[0075] 5. Antibacterial activity of crude lipopeptide against kiwifruit soft rot pathogens

[0076] from Figure 8 It can be seen that under the same culture conditions, the growth of the strain treated with crude lipopeptide was significantly different from that of the control strain. As shown in Table 4, the inhibition rates of the crude lipopeptide solution against the pathogens Alternaria alternata, Phomopsis spp., and Botrytis cinerea were 74.00±1.73%, 61.33±0.67%, and 85.33±0.58%, respectively, showing significant differences in antibacterial activity. Figure 9 It can be seen that the mycelia of pathogens treated with crude lipopeptide all showed abnormalities, among which the most significant mutation effect was in the mycelia of Botrytis cinerea, where local mycelium swelling occurred.

[0077] Table 4 Antibacterial activity of 100 mg / L crude lipopeptide against kiwifruit soft rot pathogens

[0078]

[0079] Note: The data in the table are mean ± standard error, and lowercase letters indicate significant differences at the 0.05 level.

[0080] 6. Antagonistic peptide gene detection results of Bacillus subtilis

[0081] The PCR test results are shown in Table 5. Figure 10As shown in the table, there are 17 pairs of primers, of which 3 pairs were negative, namely fenA F / R, pmxC F / R, and ituD F / R, and there were no obvious fluorescent bands in the electrophoresis pattern, suggesting that Bacillus subtilis may not be able to synthesize the antibacterial peptides Iturin and Polymyxin; the remaining 14 pairs of primers were positive in the table and produced a single fluorescent band on the electrophoresis pattern, thus proving that Bacillus subtilis has genes for synthesizing the antibacterial peptides Surfactin, Bas iliskamideA / Thai lanstatinB, Bacillibactin, Bacillaene, Fengycin, Bacilysin, Subti losinA, and Luminmide.

[0082] Table 5 Antibacterial related gene detection

[0083]

[0084]

[0085] Note: "+" indicates the presence of the gene, "-" indicates the absence of the gene, and negative is ddH20.

[0086] Table 6 Sequence Listing of SEQ ID NO: 1-SEQ ID NO: 34

[0087]

[0088]

[0089] Anything not described in detail in the present invention is well known to those skilled in the art.

[0090] The basic principles, main features, and advantages of the present invention are shown and described above. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are merely illustrative of the principles of the present invention. Various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. Such changes and modifications are intended to fall within the scope of the present invention. The scope of protection claimed in the present invention is defined by the appended claims and their equivalents.

Claims

1. A biopesticide preparation prepared using Bacillus subtilis metabolites, characterized in that: The biopesticide preparation comprises metabolites extracted from the fermentation process of Bacillus subtilis, wherein the metabolites include crude protein and crude lipopeptide extracted from the sterile fermentation broth or high-temperature sterile fermentation broth of Bacillus subtilis, and one or a combination of antimicrobial peptides synthesized via specific target genes.

2. The biopesticide preparation prepared by using Bacillus subtilis metabolites according to claim 1, characterized in that: The specific target gene is an antimicrobial peptide synthesis gene determined by PCR detection using 14 pairs of primers; The synthetic antimicrobial peptides include one or a combination of Surfactin, BasiliskamideA / ThailanstatinB, Bacillibactin, Bacillaene, Fengycin, Bacilysin, SubtilosinA and Luminmide.

3. The biopesticide preparation prepared by using Bacillus subtilis metabolites according to claim 1, characterized in that: The 14 pairs of primers have 16S rDNA sequences shown in SEQ ID NO: 1 to SEQ ID NO:

30.

4. The biopesticide preparation prepared by using Bacillus subtilis metabolites according to claim 1, characterized in that: The biopesticide preparation contains one or more adjuvants, and the adjuvants are selected from at least one or a combination of the following: non-ionic surfactant, stabilizer, wetting agent, and sustained-release agent.

5. A method for preparing a biological pesticide formulation as claimed in any one of claims 1 to 4, characterized in that: The steps include: Cultivate Bacillus subtilis in a suitable culture medium for 96 hours to obtain a bacterial solution rich in metabolites; The sterile fermentation broth is obtained by centrifugation and filtration techniques; The sterile fermentation liquid was diluted to determine the dilution multiple with the best antibacterial effect on the pathogen of kiwifruit soft rot; Metabolites with significant antibacterial activity are further enriched through crude protein extraction and crude lipopeptide separation technology; the metabolites obtained in the above steps are formulated to form a biopesticide formulation that is easy to apply.

6. The method for preparing the biopesticide formulation according to claim 5, characterized in that: The formulation process further comprises the following steps: mixing the crude protein and crude lipopeptide obtained by extraction and separation with a proper amount of stabilizer to form a stable metabolite solution; The pH of the metabolite solution was adjusted to 6.5 to 7.5 to optimize the activity of the antimicrobial peptides; adding a wetting agent and a nonionic surfactant to the metabolite solution to improve the wettability and adhesion of the formulation on the plant surface; Sustained-release agents are added to control the release rate of metabolites and extend the shelf life of the preparation; The metabolite solution is converted into a powder or granular preparation by spray drying or freeze drying technology for easy storage and administration.

7. The method for preparing a biological pesticide formulation according to claim 6, wherein the nonionic surfactant is used in an amount of 0.1% to 1.0% of the total weight of the formulation; the stabilizer is used in an amount of 0.05% to 0.5% of the total weight of the formulation; the wetting agent is used in an amount of 0.2% to 1.5% of the total weight of the formulation; and the sustained-release agent is used in an amount of 1.0% to 3.0% of the total weight of the formulation.

8. Use of the biological pesticide preparation according to any one of claims 1 to 5 in the prevention and treatment of kiwifruit diseases.

9. Use of the biological pesticide preparation according to claim 8 in the prevention and treatment of kiwifruit diseases, characterized in that: The use is to change the morphological structure of pathogenic fungus hyphae through Bacillus subtilis metabolites, thereby inhibiting the growth of pathogenic fungi.

10. Use of the biological pesticide preparation according to claim 9 in the prevention and treatment of kiwifruit diseases, characterized in that: The pathogenic bacteria include Botrytis cinerea, Alternaria alternata and Phomopsis spp.

Citation Information

Cited By

  • Bacillus tequilensis P61 and application of bacillus tequilensis P61 in prevention and treatment of kiwi fruit soft rot

    CN120272359A